|
|
Blood, 15 March 2005, Vol. 105, No. 6, pp. 2480-2486.
Prepublished online as a Blood First Edition Paper on November 30, 2004; DOI 10.1182/blood-2004-06-2103.
 Previous Article | Table of Contents | Next Article 
IMMUNOBIOLOGY
Regulation of human auto- and alloreactive T cells by indoleamine 2,3-dioxygenase (IDO)–producing dendritic cells: too much ado about IDO?
Peter Terness,
Jing-Jing Chuang,
Thomas Bauer,
Lucian Jiga, and
Gerhard Opelz
From the Institute of Immunology, Department of Transplantation Immunology, University of Heidelberg, Heidelberg, Germany.
Although dendritic cells (DCs) strongly stimulate the immune response, they can also induce unresponsiveness. Recently, a human monocyte-derived DC subpopulation was described that constitutively expresses indoleamine 2,3-dioxygenase (IDO). These DCs were defined as nonadherent CD123+/CC chemokine receptor 6+ (CCR6+) cells that suppress the allogeneic T-cell response. In the present study, we generated nonadherent, mature DCs from human blood monocytes. As expected, in addition to the classic markers, these cells expressed CD123 and CCR6. Reverse transcription–polymerase chain reaction (RT-PCR), however, did not show IDO gene transcription, nor did we detect enzymatic IDO activity. Treating the cells with interferon- (IFN-) resulted in significant IDO production. Subsequently, we studied the regulatory properties of IDO-producing DCs on autologous and allogeneic T-cell responses. Neither OKT3-stimulated T cells of healthy donors nor myelin basic protein (MBP)–specific T cells of patients with multiple sclerosis (MS) were suppressed by autologous IDO DCs. However, whereas IDOneg DCs supported further stimulation of preactivated MBP-specific T cells of an MS patient, IDOpos DCs had lost this capacity. The allogeneic T-cell response was only marginally suppressed by IDO DCs. Our findings show that nonadherent CD123+/CCR6+ human DCs do not constitutively express IDO, and, even if they express the enzyme after IFN- treatment, they possess only limited T-cell regulatory function.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
Related Letter in Blood Online:
-
Dendritic cells have the option to express IDO-mediated suppression or not
- David H. Munn, Andrew L. Mellor, Marco Rossi, and James W. Young
Blood 2005 105: 2618.
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
S. Rutella, S. Danese, and G. Leone
Tolerogenic dendritic cells: cytokine modulation comes of age
Blood,
September 1, 2006;
108(5):
1435 - 1440.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Agaugue, L. Perrin-Cocon, F. Coutant, P. Andre, and V. Lotteau
1-Methyl-Tryptophan Can Interfere with TLR Signaling in Dendritic Cells Independently of IDO Activity
J. Immunol.,
August 15, 2006;
177(4):
2061 - 2071.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Orabona, P. Puccetti, C. Vacca, S. Bicciato, A. Luchini, F. Fallarino, R. Bianchi, E. Velardi, K. Perruccio, A. Velardi, et al.
Toward the identification of a tolerogenic signature in IDO-competent dendritic cells
Blood,
April 1, 2006;
107(7):
2846 - 2854.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Luft, E. Maraskovsky, and M. Schnurr
IDO production, adaptive immunity, and CTL killing
Blood,
October 1, 2005;
106(7):
2228 - 2229.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Braun, R. S. Longman, and M. L. Albert
A two-step induction of indoleamine 2,3 dioxygenase (IDO) activity during dendritic-cell maturation
Blood,
October 1, 2005;
106(7):
2375 - 2381.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. H. Munn, A. L. Mellor, M. Rossi, and J. W. Young
Dendritic cells have the option to express IDO-mediated suppression or not
Blood,
March 15, 2005;
105(6):
2618 - 2618.
[Full Text]
[PDF]
|
|
|
|
|
